7
are currently without
evidence of disease.
No non-hematologic Grade 4 adverse events were reported. Grade 4
lymphopenia, neutropenia
and thrombocytopenia were observed in 1, 2 and 2 patients,
respectively. Grade 1-3 anemia,
nausea/vomiting and hypocalcemia were observed in 18, 1, and 3
patients, respectively.
“Myelosuppression, particularly neutropenia, is a substantial
clinical problem in patients with
relapsed NHL,” said Dr. Scott E. Smith, MD, PhD, Assistant
Professor of Medicine at Loyola,
who was the principal investigator of this trial. “Based on
these favorable results, we have
organized a followup trial of GaRD used in combination with another
standard regimen that we
expect to initiate in a Chicago-based clinical
collaboration.”
About Ganite
Ganite was originally developed by the U.S. National Cancer
Institute as a cancer chemotherapy
drug. A separate series of studies showed that the drug markedly
reduced the loss of calcium
from bone - an observation that suggested the drug may be useful in
hypercalcemia, as well as
other conditions associated with loss of bone mass. Ganite is
approved in the U.S. for treatment
of symptomatic patients with cancer related hypercalcemia that is
resistant to hydration.
Important Safety Information about Ganite® (gallium nitrate
injection)
Ganite is contraindicated in patients with severe renal impairment
(serum creatinine > 2.5
mg/dL). While Ganite was generally well tolerated by patients who
received the drug in clinical
trials, concurrent use of Ganite with other potentially nephrotoxic
drugs like aminoglycosides
and amphotericin B may increase the risk for developing severe
renal insufficiency in patients
with cancer-relapsed hypercalcemia. If use of a potentially
nephrotoxic drug is indicated during
Ganite therapy, Ganite should be disconti
'"/>Page: 1 2 3 4 5 Related medicine technology :1.
Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer2.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis3.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial4.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis5.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone6.
Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis7.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease8.
NexMed Announces Completion of Patient Enrollment in Two Pivotal
Phase 3 Studies for Anti-Fungal Product9.
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis10.
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery11.
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery